Wednesday's Small-Cap Winners & Losers
Critical Therapeutics (CRTX) surged 25% after Merck KGaA affiliate Dey agreed to co-promote two of the Lexington, Mass., biotech's zileuton asthma drugs, one of which is still awaiting approval by the Food and Drug Administration. Critical Therapeutics will additionally help promote one of Dey's drug candidates, should it receive regulatory approval. The deal's financial terms weren't disclosed. Shares were up 45 cents to $2.25.
Evolving Systems (EVOL) posted nickel-a-share profits for the fourth quarter -- a 1-cent climb from last year that tops the only analyst's estimate by 2 cents, according to Thomson Financial. Revenue dropped 13% to $8.8 million from a year ago, but this tops the sole target by $300,000. Shares of the Englewood, Colo., technical-software company were up $1.67, or 12.6%, to $1.88.
MedAvant Healthcare Solutions (PILL) plummeted 35.6% after the Norcross, Ga., medical-transaction processor said stockholders' equity sank 17% year over year to $27.4 million in the fourth quarter. Revenue fell 8% to $15.8 million. Losses narrowed to $1.6 million, or 12 cents a share, from 14 cents a share last year, but shares were still off $1.77, at $3.20.
First Consulting Group (FCGI), a Long Beach, Calif., business-services firm, tumbled 23% after posting fourth-quarter profits of $5.1 million, or 19 cents a share, which missed consensus estimates by 2 cents a share even though it reversed a year-ago 41-cent loss. The company also expects first-quarter revenue of between $64 million and $66 million, which misses Street expectations by at least $4.9 million. Shares were down $2.68, to $8.98.Waste-management company Clean Harbors (CLHB) fell 3 cents short of fourth-quarter per-share estimates despite ratcheting up its profits to 56 cents a share, compared with 43 cents a year ago. The Norwell, Mass., firm was losing $6.15, or 12.1%, to $44.75 in recent trading.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV